John Carroll

A crash course.

The Accelerated Approval Debate: Faster FDA Drug Approvals May Mean Less Efficacy Data

Everyone wants in, but with no ground rules, the biosimilar business remains elusive.

Oral multiple sclerosis agents look to gain market share.

Biogenetic tests emerge from their chrysalis.

Traversing the Landscape Of Project BioShield.

Better drug discovery through better target identification.

Pharmacovigilance: the new drug-development standard.

One drug, many uses.

As REMS Requirements Simplify, Participants Need To Catch Up.